The risk or severity of adverse effects can be increased when Diclofenac is combined with Nabumetone. The risk or severity of adverse effects can be increased when Diclofenac is combined with Desoxycorticosterone Pivalate. The risk or severity of adverse effects can be increased when Diclofenac is combined with Meclofenamic acid. The risk or severity of adverse effects can be increased when Cilazapril is combined with Diclofenac. The metabolism of Diclofenac can be decreased when combined with Lovastatin. Diclofenac may increase the neuroexcitatory activities of Pefloxacin. The risk or severity of adverse effects can be increased when Diclofenac is combined with Higenamine. The risk or severity of adverse effects can be increased when Diclofenac is combined with Kebuzone. Diclofenac may increase the anticoagulant activities of Ethyl biscoumacetate. The metabolism of Diclofenac can be decreased when combined with Fluvastatin. Diclofenac may decrease the antihypertensive activities of Bufuralol. The therapeutic efficacy of Metolazone can be decreased when used in combination with Diclofenac. The metabolism of Diclofenac can be decreased when combined with Topiroxostat. The metabolism of Diclofenac can be decreased when combined with Boceprevir. The risk or severity of adverse effects can be increased when Diclofenac is combined with Zomepirac. The risk or severity of adverse effects can be increased when Diclofenac is combined with Mycophenolate mofetil. The metabolism of Diclofenac can be decreased when combined with Fluvoxamine. The metabolism of Diclofenac can be decreased when combined with Lobeglitazone. Diclofenac may decrease the excretion rate of Amrubicin which could result in a higher serum level. Diclofenac may increase the anticoagulant activities of Troxerutin. Diclofenac may increase the anticoagulant activities of Ancrod. Diclofenac may increase the neuroexcitatory activities of Enoxacin. The risk or severity of adverse effects can be increased when Diclofenac is combined with Flurbiprofen. The therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Diclofenac. The metabolism of Diclofenac can be decreased when combined with Erythromycin. The risk or severity of adverse effects can be increased when Diclofenac is combined with Tiludronic acid. The risk or severity of adverse effects can be increased when Candesartan is combined with Diclofenac. The metabolism of Diclofenac can be decreased when combined with Irbesartan. The metabolism of Diclofenac can be decreased when combined with Felodipine. The risk or severity of adverse effects can be increased when Diclofenac is combined with Atamestane. The risk or severity of adverse effects can be increased when Diclofenac is combined with Phenylbutazone. The serum concentration of Diclofenac can be increased when it is combined with Probenecid. Diclofenac may decrease the diuretic activities of Furosemide. The risk or severity of adverse effects can be increased when Diclofenac is combined with Zileuton. The therapeutic efficacy of Prostaglandin G2 can be decreased when used in combination with Diclofenac. Diclofenac may increase the anticoagulant activities of Pentaerythritol Tetranitrate. The metabolism of Diclofenac can be decreased when combined with Rosiglitazone. The metabolism of Diclofenac can be decreased when combined with Dronedarone. The risk or severity of adverse effects can be increased when Diclofenac is combined with Halcinonide. The risk or severity of adverse effects can be increased when Diclofenac is combined with Benzydamine. The therapeutic efficacy of Epoprostenol can be decreased when used in combination with Diclofenac. The serum concentration of Diclofenac can be increased when it is combined with Palbociclib. Diclofenac may decrease the excretion rate of GPX-150 which could result in a higher serum level. Diclofenac may increase the neuroexcitatory activities of Grepafloxacin. The serum concentration of Diclofenac can be increased when it is combined with Sulfisoxazole. Diclofenac may increase the anticoagulant activities of Ardeparin. The metabolism of Diclofenac can be decreased when combined with Clarithromycin. Diclofenac may decrease the excretion rate of Spectinomycin which could result in a higher serum level. Diclofenac may decrease the excretion rate of SP1049C which could result in a higher serum level. The serum concentration of Diclofenac can be increased when it is combined with Netupitant. Diclofenac may decrease the antihypertensive activities of Sotalol. The therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Diclofenac. Diclofenac may decrease the excretion rate of Kanamycin which could result in a higher serum level. Diclofenac may decrease the antihypertensive activities of Propranolol. The risk or severity of adverse effects can be increased when Fimasartan is combined with Diclofenac. The risk or severity of adverse effects can be increased when Diclofenac is combined with Fludrocortisone. The serum concentration of Diclofenac can be decreased when it is combined with Secobarbital. The risk or severity of adverse effects can be increased when Diclofenac is combined with Androstenedione. The therapeutic efficacy of Tafluprost can be decreased when used in combination with Diclofenac. Diclofenac may decrease the excretion rate of Plazomicin which could result in a higher serum level. The metabolism of Diclofenac can be decreased when combined with Clopidogrel. The therapeutic efficacy of Unoprostone can be decreased when used in combination with Diclofenac. Diclofenac may decrease the antihypertensive activities of Eplerenone. The metabolism of Diclofenac can be decreased when combined with Nelfinavir. Diclofenac may decrease the excretion rate of Zoptarelin doxorubicin which could result in a higher serum level. Diclofenac may increase the anticoagulant activities of Becaplermin. The risk or severity of adverse effects can be increased when Diclofenac is combined with Amcinonide. The risk or severity of adverse effects can be increased when Diclofenac is combined with Olopatadine. The risk or severity of adverse effects can be increased when Diclofenac is combined with Zoledronic acid. Diclofenac may increase the anticoagulant activities of Fondaparinux. The serum concentration of Colchicine can be increased when it is combined with Diclofenac. Diclofenac may increase the anticoagulant activities of Dextran 75. Diclofenac may increase the anticoagulant activities of Warfarin. The risk or severity of adverse effects can be increased when Forasartan is combined with Diclofenac. The serum concentration of Diclofenac can be increased when it is combined with Fusidic Acid. The risk or severity of adverse effects can be increased when Diclofenac is combined with Ciclesonide. The therapeutic efficacy of Lubiprostone can be decreased when used in combination with Diclofenac. The risk or severity of adverse effects can be increased when Diclofenac is combined with Equilin. Diclofenac may decrease the excretion rate of Geneticin which could result in a higher serum level. The risk or severity of adverse effects can be increased when Diclofenac is combined with NCX 1022. Diclofenac may decrease the excretion rate of Paromomycin which could result in a higher serum level. The metabolism of Diclofenac can be decreased when combined with Losartan. The therapeutic efficacy of Polythiazide can be decreased when used in combination with Diclofenac. Diclofenac may decrease the antihypertensive activities of Labetalol. The risk or severity of adverse effects can be increased when Diclofenac is combined with ME-609. The risk or severity of adverse effects can be increased when Diclofenac is combined with Beclomethasone dipropionate. The serum concentration of Ranolazine can be increased when it is combined with Diclofenac. The risk or severity of adverse effects can be increased when Diclofenac is combined with Nitroaspirin. The therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Diclofenac. The risk or severity of adverse effects can be increased when Diclofenac is combined with Salicylic acid. Diclofenac may decrease the antihypertensive activities of Practolol. The serum concentration of Diclofenac can be decreased when it is combined with Tocilizumab. The risk or severity of adverse effects can be increased when Diclofenac is combined with Indobufen. The risk or severity of adverse effects can be increased when Diclofenac is combined with Isoxicam. The risk or severity of adverse effects can be increased when Diclofenac is combined with Aceclofenac. The risk or severity of adverse effects can be increased when Diclofenac is combined with Alclometasone. The risk or severity of bleeding can be increased when Betrixaban is combined with Diclofenac. The risk or severity of adverse effects can be increased when Diclofenac is combined with Omacetaxine mepesuccinate. Diclofenac may decrease the excretion rate of Amikacin which could result in a higher serum level. Diclofenac may decrease the antihypertensive activities of Landiolol. Diclofenac may increase the anticoagulant activities of Heparin. The metabolism of Diclofenac can be decreased when combined with Eslicarbazepine acetate. The serum concentration of Pazopanib can be increased when it is combined with Diclofenac. The risk or severity of adverse effects can be increased when Diclofenac is combined with Tranilast. The metabolism of Diclofenac can be decreased when combined with Fluoxetine. The serum concentration of Diclofenac can be decreased when it is combined with Carbamazepine. The serum concentration of Diclofenac can be decreased when it is combined with Rifapentine. The risk or severity of adverse effects can be increased when Diclofenac is combined with Tiaprofenic acid. Diclofenac may increase the neuroexcitatory activities of Sparfloxacin. Diclofenac may increase the anticoagulant activities of Lepirudin. The risk or severity of adverse effects can be increased when Diclofenac is combined with Niflumic Acid. The serum concentration of Diclofenac can be decreased when it is combined with Siltuximab. Diclofenac may decrease the excretion rate of Apramycin which could result in a higher serum level. The risk or severity of adverse effects can be increased when Ramipril is combined with Diclofenac. The serum concentration of Diclofenac can be increased when it is combined with Vemurafenib. The risk or severity of adverse effects can be increased when Enalapril is combined with Diclofenac. The metabolism of Diclofenac can be decreased when combined with Idelalisib. Diclofenac may decrease the excretion rate of Tobramycin which could result in a higher serum level. Diclofenac may decrease the antihypertensive activities of Bopindolol. The risk or severity of adverse effects can be increased when Diclofenac is combined with Felbinac. The serum concentration of Edoxaban can be increased when it is combined with Diclofenac. The metabolism of Diclofenac can be decreased when combined with Topiramate. The serum concentration of Topotecan can be increased when it is combined with Diclofenac. The risk or severity of adverse effects can be increased when Diclofenac is combined with Antipyrine. The risk or severity of adverse effects can be increased when Lisinopril is combined with Diclofenac. The metabolism of Diclofenac can be decreased when combined with Cobicistat. Diclofenac may decrease the excretion rate of Gentamicin which could result in a higher serum level. Diclofenac may increase the anticoagulant activities of Phenindione. The risk or severity of adverse effects can be increased when Diclofenac is combined with Semapimod. The risk or severity of adverse effects can be increased when Diclofenac is combined with Fluticasone propionate.